{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:43:43Z","timestamp":1793497423601,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s12325-024-02914-w","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T09:01:54Z","timestamp":1719306114000},"page":"3196-3216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Simulation Study of the Effect of Clinical Characteristics and Treatment Choice on Reliever Medication Use, Symptom Control and Exacerbation Risk in Moderate\u2013Severe Asthma"],"prefix":"10.1007","volume":"41","author":[{"given":"Gabriel","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2799-7643","authenticated-orcid":false,"given":"Sven C.","family":"van Dijkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-5973","authenticated-orcid":false,"given":"Ian","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4346-0088","authenticated-orcid":false,"given":"Sean","family":"Oosterholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourabh","family":"Fulmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8047-9378","authenticated-orcid":false,"given":"Anurita","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6211-1430","authenticated-orcid":false,"given":"Oscar","family":"Della Pasqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"2","key":"2914_CR1","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0037-2021","volume":"17","author":"J Holmes","year":"2021","unstructured":"Holmes J, Heaney LG. Measuring adherence to therapy in airways disease. Breathe. 2021;17(2):210037.","journal-title":"Breathe"},{"key":"2914_CR2","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/ppul.25347","volume":"56","author":"YP Tsang","year":"2021","unstructured":"Tsang YP, Marchant JM, Li AM, Chang AB. Stability of sputum inflammatory phenotypes in childhood asthma during stable and exacerbation phases. Pediatr Pulmonol. 2021;56:1484\u20139.","journal-title":"Pediatr Pulmonol"},{"key":"2914_CR3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/B978-1-4557-3383-5.00041-5","volume-title":"Murray and Nadel's textbook of respiratory medicine","author":"PG Woodruff","year":"2016","unstructured":"Woodruff PG, Bhakta NR, Fahy JV. Asthma: pathogenesis and phenotypes. In: Broaddus VC, Mason RJ, Ernst JD, et al. editors. Murray and Nadel\u2019s textbook of respiratory medicine. 6th ed. W.B. Saunders; 2016. p. 713\u2013730.e7.","edition":"6"},{"issue":"9","key":"2914_CR4","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/cea.12138","volume":"43","author":"T Janssens","year":"2013","unstructured":"Janssens T, Ritz T. Perceived triggers of asthma: key to symptom perception and management. Clin Exp Allergy. 2013;43(9):1000\u20138.","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"2914_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s43441-019-00065-7","volume":"54","author":"B Ratitch","year":"2020","unstructured":"Ratitch B, Goel N, Mallinckrodt C, et al. Defining efficacy estimands in clinical trials: examples illustrating ICH E9(R1) guidelines. Ther Innov Regul Sci. 2020;54(2):370\u201384.","journal-title":"Ther Innov Regul Sci"},{"issue":"51\u201352","key":"2914_CR6","first-page":"883","volume":"118","author":"M Pohl","year":"2021","unstructured":"Pohl M, Baumann L, Behnisch R, Kirchner M, Krisam J, Sander A. Estimands-a basic element for clinical trials. Dtsch Arztebl Int. 2021;118(51\u201352):883\u20138.","journal-title":"Dtsch Arztebl Int"},{"key":"2914_CR7","volume":"2013","author":"F Braido","year":"2013","unstructured":"Braido F. Failure in asthma control: reasons and consequences. Scientifica (Cairo). 2013;2013:549252.","journal-title":"Scientifica (Cairo)"},{"issue":"4","key":"2914_CR8","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jaip.2017.05.001","volume":"5","author":"JR Castillo","year":"2017","unstructured":"Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918\u201327.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"2914_CR9","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2213-2600(17)30053-X","volume":"5","author":"B Lipworth","year":"2017","unstructured":"Lipworth B, Jabbal S. Debate on long-acting \u03b2 agonists for asthma: they think it\u2019s all over. Lancet Respir Med. 2017;5(3):e14\u20135.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2914_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1586\/17512433.2016.1093415","volume":"9","author":"CS Ulrik","year":"2016","unstructured":"Ulrik CS. Asthma symptoms in obese adults: the challenge of achieving asthma control. Expert Rev Clin Pharmacol. 2016;9(1):5\u20138.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"11","key":"2914_CR11","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1111\/bcp.15801","volume":"89","author":"S Oosterholt","year":"2023","unstructured":"Oosterholt S, Pavord ID, Brusselle G, et al. Modelling Asthma TrEatment Responses (MASTER): effect of individual patient characteristics on the risk of exacerbation in moderate or severe asthma\u2014a time-to-event analysis of randomized clinical trials. Br J Clin Pharmacol. 2023;89(11):3273\u201390.","journal-title":"Br J Clin Pharmacol"},{"key":"2914_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41533-022-00310-x","volume":"32","author":"M Vervloet","year":"2022","unstructured":"Vervloet M, van Dijk L, Weesie YM, Kocks JWH, Dima AL, Korevaar JC. Understanding relationships between asthma medication use and outcomes in a SABINA primary care database study. Prim Care Respir Med. 2022;32:43.","journal-title":"Prim Care Respir Med"},{"issue":"1","key":"2914_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41533-019-0156-4","volume":"29","author":"V Kritikos","year":"2019","unstructured":"Kritikos V, Price D, Papi A, et al. A multinational observational study identifying primary care patients at risk of overestimation of asthma control. NPJ Prim Care Respir Med. 2019;29(1):43.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"6","key":"2914_CR14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2500\/aap.2019.40.4259","volume":"40","author":"PA Greenberger","year":"2019","unstructured":"Greenberger PA. Lessons learned from clinical trials of asthma. Allergy Asthma Proc. 2019;40(6):410\u20133.","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"2914_CR15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jaip.2016.11.007","volume":"5","author":"JD Blakey","year":"2017","unstructured":"Blakey JD, Price DB, Pizzichini E, et al. Identifying risk of future asthma attacks using UK medical record data: a respiratory effectiveness group initiative. J Allergy Clin Immunol Pract. 2017;5(4):1015-1024.e8.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"2914_CR16","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s12325-023-02774-w","volume":"41","author":"S van Dijkman","year":"2024","unstructured":"van Dijkman S, Yorganc\u0131o\u011flu A, Pavord I, et al. Effect of individual patient characteristics and treatment choices on reliever medication use in moderate-severe asthma: a Poisson analysis of randomised clinical trials. Advan Ther. 2024;41(3):1201\u201325.","journal-title":"Advan Ther"},{"issue":"1","key":"2914_CR17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12325-021-01976-4","volume":"39","author":"P Daley-Yates","year":"2022","unstructured":"Daley-Yates P, Aggarwal B, Lulic Z, Fulmali S, Cruz AA, Singh D. Pharmacology versus convenience: a benefit\/risk analysis of regular maintenance versus infrequent or as-needed inhaled corticosteroid use in mild asthma. Adv Ther. 2022;39(1):706\u201326.","journal-title":"Adv Ther"},{"issue":"10","key":"2914_CR18","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1109\/JBHI.2021.3090469","volume":"25","author":"M Viceconti","year":"2021","unstructured":"Viceconti M, Emili L, Afshari P, et al. Possible contexts of use for in silico trials methodologies: a consensus-based review. IEEE J Biomed Health Inform. 2021;25(10):3977\u201382.","journal-title":"IEEE J Biomed Health Inform"},{"issue":"10","key":"2914_CR19","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1007\/s12325-023-02590-2","volume":"40","author":"D Singh","year":"2023","unstructured":"Singh D, Oosterholt S, Pavord I, Garcia G, Abhijith PG, Della Pasqua O. Understanding the clinical implications of individual patient characteristics and treatment choice on the risk of exacerbation in asthma patients with moderate-severe symptoms. Adv Ther. 2023;40(10):4606\u201325.","journal-title":"Adv Ther"},{"key":"2914_CR20","first-page":"111","volume":"14","author":"C Kallis","year":"2023","unstructured":"Kallis C, Calvo RA, Schuller B, Quint JK. Development of an asthma exacerbation risk prediction model for conversational use by adults in England. Pragmat Obs Res. 2023;14:111\u201325.","journal-title":"Pragmat Obs Res"},{"key":"2914_CR21","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/bcp.12151","volume":"76","author":"AS Chain","year":"2013","unstructured":"Chain AS, Dieleman JP, van Noord C, et al. Not-in-trial simulation I: bridging cardiovascular risk from clinical trials to real-life conditions. Br J Clin Pharmacol. 2013;76:964\u201372.","journal-title":"Br J Clin Pharmacol"},{"key":"2914_CR22","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1111\/bcp.14682","volume":"87","author":"S D'Agate","year":"2021","unstructured":"D\u2019Agate S, Chavan C, Manyak M, et al. Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms. Br J Clin Pharmacol. 2021;87:2777\u201389.","journal-title":"Br J Clin Pharmacol"},{"key":"2914_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/clpt.2009.107","volume":"86","author":"G Santen","year":"2009","unstructured":"Santen G, Horrigan J, Danhof M, et al. From trial and error to trial simulation: part 2\u2014an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. Clin Pharmacol Ther. 2009;86:255\u201362.","journal-title":"Clin Pharmacol Ther"},{"key":"2914_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1471-2288-13-92","volume":"13","author":"L Thabane","year":"2013","unstructured":"Thabane L, Mbuagbaw L, Zhang S, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol. 2013;13:92.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"2914_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/1740774510367811","volume":"7","author":"BL Egleston","year":"2010","unstructured":"Egleston BL, Cropsey KL, Lazev AB, Heckman CJ. A tutorial on principal stratification-based sensitivity analysis: application to smoking cessation studies. Clin Trials. 2010;7(3):286\u201398.","journal-title":"Clin Trials"},{"key":"2914_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"issue":"3 Suppl","key":"2914_CR27","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.jaci.2011.12.983","volume":"129","author":"A Fuhlbrigge","year":"2012","unstructured":"Fuhlbrigge A, Peden D, Apter AJ, et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol. 2012;129(3 Suppl):S34\u201348.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"2914_CR28","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2213-2600(20)30178-8","volume":"8","author":"RN van Zyl-Smit","year":"2020","unstructured":"van Zyl-Smit RN, Kr\u00fcll M, Gessner C, et al. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase\u00a03 study. Lancet Respir Med. 2020;8(10):987\u201399.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2914_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/bcp.14406","volume":"87","author":"P Daley-Yates","year":"2021","unstructured":"Daley-Yates P, Brealey N, Thomas S, et al. Therapeutic index of inhaled corticosteroids in asthma: a dose-response comparison on airway hyperresponsiveness and adrenal axis suppression. Br J Clin Pharmacol. 2021;87(2):483\u201393.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2914_CR30","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bcp.12637","volume":"80","author":"PT Daley-Yates","year":"2015","unstructured":"Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372\u201380.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2914_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s13300-018-0384-6","volume":"9","author":"B Silver","year":"2018","unstructured":"Silver B, Ramaiya K, Andrew SB, et al. EADSG guidelines: insulin therapy in diabetes. Diabetes Ther. 2018;9(2):449\u201392.","journal-title":"Diabetes Ther"},{"issue":"9","key":"2914_CR32","first-page":"929","volume":"24","author":"J Fishman","year":"2018","unstructured":"Fishman J, Kalilani L, Song Y, Swallow E, Wild I. Antiepileptic drug titration and related health care resource use and costs. J Manag Care Spec Pharm. 2018;24(9):929\u201338.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"2914_CR33","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s12325-022-02092-7","volume":"39","author":"D Singh","year":"2022","unstructured":"Singh D, Garcia G, Maneechotesuwan K, et al. New versus old: the impact of changing patterns of inhaled corticosteroid prescribing and dosing regimens in asthma management. Adv Ther. 2022;39(5):1895\u2013914.","journal-title":"Adv Ther"},{"issue":"3","key":"2914_CR34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1183\/09031936.00155307","volume":"32","author":"DR Taylor","year":"2008","unstructured":"Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J. 2008;32(3):545\u201354.","journal-title":"Eur Respir J"},{"issue":"2","key":"2914_CR35","doi-asserted-by":"publisher","first-page":"T150","DOI":"10.1016\/j.arbres.2021.05.032","volume":"58","author":"V Plaza","year":"2022","unstructured":"Plaza V, Alobid I, Alvarez C, et al. Spanish asthma management guidelines (GEMA) v.5.1: highlights and controversies. Arch Bronconeumol. 2022;58(2):T150\u20138.","journal-title":"Arch Bronconeumol"},{"issue":"2","key":"2914_CR36","doi-asserted-by":"publisher","first-page":"2300700","DOI":"10.1183\/13993003.00700-2023","volume":"62","author":"M Cazzola","year":"2023","unstructured":"Cazzola M, Page CP, Matera MG, Rogliani P, Hanania NA. Revisiting asthma pharmacotherapy: where do we stand and where do we want to go? Eur Respir J. 2023;62(2):2300700.","journal-title":"Eur Respir J"},{"key":"2914_CR37","first-page":"1512","volume":"2011","author":"RJ Dennis","year":"2011","unstructured":"Dennis RJ, Solarte I, Rodrigo G. Asthma in adults. BMJ Clin Evid. 2011;2011:1512.","journal-title":"BMJ Clin Evid"},{"issue":"2","key":"2914_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.pop.2023.01.001","volume":"50","author":"H Nguyen","year":"2023","unstructured":"Nguyen H, Nasir M. Management of chronic asthma in adults. Prim Care. 2023;50(2):179\u201390.","journal-title":"Prim Care"},{"issue":"4","key":"2914_CR39","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.jaip.2020.11.013","volume":"9","author":"OD Tupper","year":"2021","unstructured":"Tupper OD, H\u00e5kansson KEJ, Ulrik CS. Remission and changes in severity over 30\u00a0years in an adult asthma cohort. J Allergy Clin Immunol Pract. 2021;9(4):1595\u20131603.e5.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"2914_CR40","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/resp.14610","volume":"28","author":"M Thomas","year":"2023","unstructured":"Thomas M, Beasley R. The treatable traits approach to adults with obstructive airways disease in primary and secondary care. Respirology. 2023;28(12):1101\u201316.","journal-title":"Respirology"},{"key":"2914_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-020-00785-1","volume":"42","author":"J Stern","year":"2020","unstructured":"Stern J, Pier J, Litonjua AA. Asthma epidemiology and risk factors. Semin Immunopathol. 2020;42:5\u201315.","journal-title":"Semin Immunopathol"},{"issue":"1","key":"2914_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.29262\/ram.v68i1.756","volume":"68","author":"M Robles-Figueroa","year":"2021","unstructured":"Robles-Figueroa M, Flores-Razo MM. La obesidad en adultos est\u00e1 asociada con la gravedad del asma, pero no con el control del asma. Rev Alerg Mex. 2021;68(1):26\u201334.","journal-title":"Rev Alerg Mex"},{"issue":"1","key":"2914_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/cea.12435","volume":"45","author":"LP Boulet","year":"2015","unstructured":"Boulet LP. Obesity and atopy. Clin Exp Allergy. 2015;45(1):75\u201386.","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"2914_CR44","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/crj.13718","volume":"17","author":"Q Huang","year":"2023","unstructured":"Huang Q, Li Y, Li C, et al. Cigarette smoke aggravates asthma via altering airways inflammation phenotypes and remodelling. Clin Respir J. 2023;17(12):1316\u201327.","journal-title":"Clin Respir J"},{"issue":"2","key":"2914_CR45","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.amepre.2019.07.028","volume":"58","author":"DN Bhatta","year":"2020","unstructured":"Bhatta DN, Glantz SA. Association of e-cigarette use with respiratory disease among adults: a longitudinal analysis. Am J Prev Med. 2020;58(2):182\u201390.","journal-title":"Am J Prev Med"},{"issue":"2","key":"2914_CR46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jaci.2009.09.011","volume":"125","author":"MM Kelly","year":"2010","unstructured":"Kelly MM, O\u2019Connor TM, Leigh R, et al. Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma. J Allergy Clin Immunol. 2010;125(2):349\u2013356.e13.","journal-title":"J Allergy Clin Immunol"},{"issue":"23","key":"2914_CR47","doi-asserted-by":"publisher","first-page":"15285","DOI":"10.3390\/ijms232315285","volume":"23","author":"L Calzetta","year":"2022","unstructured":"Calzetta L, Chetta A, Aiello M, Pistocchini E, Rogliani P. The impact of corticosteroids on human airway smooth muscle contractility and airway hyperresponsiveness: a systematic review. Int J Mol Sci. 2022;23(23):15285.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2914_CR48","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1440-1843.2004.00557.x","volume":"9","author":"JM Wraight","year":"2004","unstructured":"Wraight JM, Smith AD, Cowan JO, Flannery EM, Herbison GP, Taylor DR. Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate. Respirology. 2004;9(2):215\u201321.","journal-title":"Respirology"},{"key":"2914_CR49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1465-9921-6-107","volume":"6","author":"S Haney","year":"2005","unstructured":"Haney S, Hancox RJ. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial. Respir Res. 2005;6:107.","journal-title":"Respir Res"},{"issue":"7","key":"2914_CR50","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1164\/rccm.201209-1739PP","volume":"187","author":"M Cazzola","year":"2013","unstructured":"Cazzola M, Page CP, Rogliani P, Matera MG. \u03b22-agonist therapy in lung disease. Am J Respir Crit Care Med. 2013;187(7):690\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"2914_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106611","volume":"188","author":"P Rogliani","year":"2021","unstructured":"Rogliani P, Beasley R, Cazzola M, Calzetta L. SMART for the treatment of asthma: a network meta-analysis of real-world evidence. Respir Med. 2021;188:106611.","journal-title":"Respir Med"},{"issue":"1","key":"2914_CR52","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12890-023-02570-w","volume":"23","author":"S Xiong","year":"2023","unstructured":"Xiong S, Chen W, Jia X, Jia Y, Liu C. Machine learning for prediction of asthma exacerbations among asthmatic patients: a systematic review and meta-analysis. BMC Pulm Med. 2023;23(1):278.","journal-title":"BMC Pulm Med"},{"issue":"4","key":"2914_CR53","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1468-2982.2005.01050.x","volume":"26","author":"HJ Maas","year":"2006","unstructured":"Maas HJ, Danhof M, Della Pasqua OE. Prediction of headache response in migraine treatment. Cephalalgia. 2006;26(4):416\u201322.","journal-title":"Cephalalgia"},{"issue":"8","key":"2914_CR54","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1468-2982.2008.01621.x","volume":"28","author":"HJ Maas","year":"2008","unstructured":"Maas HJ, Snelder N, Danhof M, Della Pasqua O. Prediction of attack frequency in migraine treatment. Cephalalgia. 2008;28(8):847\u201355.","journal-title":"Cephalalgia"},{"issue":"14","key":"2914_CR55","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jpsychires.2007.11.009","volume":"42","author":"G Santen","year":"2008","unstructured":"Santen G, Danhof M, Della Pasqua O. Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model. J Psychiatr Res. 2008;42(14):1189\u201397.","journal-title":"J Psychiatr Res"},{"issue":"8","key":"2914_CR56","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/bcp.14268","volume":"86","author":"S D'Agate","year":"2020","unstructured":"D\u2019Agate S, Wilson T, Adalig B, et al. Model-based meta-analysis of individual international prostate symptom score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms. Br J Clin Pharmacol. 2020;86(8):1585\u201399.","journal-title":"Br J Clin Pharmacol"},{"key":"2914_CR57","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/978-1-4419-7415-0_13","volume-title":"Clinical trial simulations: AAPS advances in the pharmaceutical sciences series","author":"O Della Pasqua","year":"2011","unstructured":"Della Pasqua O. PKPD and disease modeling: concepts and applications to oncology. In: Kimko H, Peck C, editors. Clinical trial simulations: AAPS advances in the pharmaceutical sciences series, vol. 1. New York: Springer; 2011. p. 281\u2013306."},{"issue":"4","key":"2914_CR58","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/cpt.1788","volume":"107","author":"S Krishnaswami","year":"2020","unstructured":"Krishnaswami S, Austin D, Della Pasqua O, et al. MID3: mission impossible or model-informed drug discovery and development? Point-counterpoint discussions on key challenges. Clin Pharmacol Ther. 2020;107(4):762\u201372.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"2914_CR59","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s11095-022-03257-3","volume":"39","author":"JS Barrett","year":"2022","unstructured":"Barrett JS, Nicholas T, Azer K, Corrigan BW. Role of disease progression models in drug development. Pharm Res. 2022;39(8):1803\u201315.","journal-title":"Pharm Res"},{"issue":"1","key":"2914_CR60","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/cpt.2856","volume":"114","author":"FT Musuamba","year":"2023","unstructured":"Musuamba FT, Cheung SYA, Colin P, et al. Moving toward a question-centric approach for regulatory decision making in the context of drug assessment. Clin Pharmacol Ther. 2023;114(1):41\u201350.","journal-title":"Clin Pharmacol Ther"},{"key":"2914_CR61","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-022123-022046","author":"KP Venkatesh","year":"2023","unstructured":"Venkatesh KP, Brito G, Kamel Boulos MN. Health digital twins in life science and health care innovation. Annu Rev Pharmacol Toxicol. 2023. https:\/\/doi.org\/10.1146\/annurev-pharmtox-022123-022046.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2914_CR62","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-0716-3449-3_4","volume":"2716","author":"S Ars\u00e8ne","year":"2024","unstructured":"Ars\u00e8ne S, Par\u00e8s Y, Tixier E, et al. In silico clinical trials: is it possible? Methods Mol Biol. 2024;2716:51\u201399.","journal-title":"Methods Mol Biol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02914-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02914-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02914-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T19:12:24Z","timestamp":1721675544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02914-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":62,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2914"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02914-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ian Pavord has received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi\/Regeneron, Menarini and GSK, and payments for organising educational events from AstraZeneca, GSK, Sanofi\/Regeneron and Teva; he has received honoraria for attending advisory panels with Genentech, Sanofi\/Regeneron, AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK; he has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, AstraZeneca, Teva and Chiesi; he has received a grant from Chiesi to support a phase\u00a02 clinical trial in Oxford; he is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed; and in 2014\u20132015\u00a0he was an expert witness for a patent dispute involving AstraZeneca and Teva; Dave Singh has received personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Epiendo, Genentech, GSK, Glenmark, Gossamerbio, Kinaset, Menarini, Novartis, Pulmatrix, Sanofi, Synairgen, Teva, Theravance and Verona; Gabriel Garcia has participated in advisory boards for GSK, AstraZeneca, Sanofi, Novartis and Boehringer Ingelheim; he has received honoraria for speaking at sponsored meetings from GSK, Boehringer Ingelheim, AstraZeneca, Sanofi, Phoenix, and Novartis; and is a principal investigator in trials sponsored by GSK, Boehringer Ingelheim, AstraZeneca, Novartis, Sanofi, PPD, Zambon, Parexel, Covance, IQVIA, and Chiesi; Sean Oosterholt, Sven van Dijkman, Sourabh Fulmali, Anurita Majumdar and Oscar Della Pasqua are GSK employees and hold stocks\/shares in GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on in silico modelling and simulation and does not contain any new studies with human participants or animals performed by any of the authors. All clinical data used for the development and validation of the models describing individual symptom score trajectories, reliever medication use and time to first exacerbation, as well as those required for generating baseline characteristics for the virtual cohorts were derived from clinical trials, which have been performed according to the Declaration of Helsinki and were approved by the required ethics committee(s) and\/or ethics review board(s). Re-use of the data for the purpose of the current investigation is in alignment with the terms of informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}